Last reviewed · How we verify

NCT04850534: SILC

Systemic Inflammation in Liver Cirrhosis

Completed Last updated 6 December 2023
What this trial tests

trial in Liver Cirrhosis in 400 participants. Completed in 30 October 2023.

Timeline
1 April 2019
Primary endpoint
31 December 2022
30 October 2023

Quick facts

Lead sponsorThird Affiliated Hospital, Sun Yat-Sen University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment400
Start date1 April 2019
Primary completion31 December 2022
Estimated completion30 October 2023
Sites1 location across China

Conditions studied

Sponsor

Third Affiliated Hospital, Sun Yat-Sen University

Who can join

Adults 18 to 75, any sex, with Liver Cirrhosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigate systemic inflammation in liver cirrhosis patients

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Enhancing hepatopathy clinical trial efficiency: a secure, large language model-powered pre-screening pipeline.
    Gui X, Lv H, Wang X, Lv L, et al · · 2025 · cited 1× · PMID 40517253 · DOI 10.1186/s13040-025-00458-5

Verify or expand the search:

Other recruiting trials for Liver Cirrhosis

Currently open trials in the same condition.

Other Third Affiliated Hospital, Sun Yat-Sen University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04850534.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing